Pharmacoeconomic and Clinical Prospective Comparison of PET-scan and MRI in Patients With de Novo Multiple Myeloma Less Than 65 Years of Age Treated According to IFM/DFCI 2009 Clinical Trial.
Phase 3
18 Years
65 Years
18 Years
65 Years
Open (Enrolling)
Both
Multiple Myeloma
Both
Multiple Myeloma
Trial Information
Pharmacoeconomic and Clinical Prospective Comparison of PET-scan and MRI in Patients With de Novo Multiple Myeloma Less Than 65 Years of Age Treated According to IFM/DFCI 2009 Clinical Trial.
Inclusion Criteria:
- symptomatic de novo multiple myeloma
- less than 65 years of age
- enrolled in the IFM/DFCI clinical trial
Exclusion Criteria:
- 66 years of age or more
- not eligible for high-dose therapy
- Cons-indications to MRI or PET-Scan
Type of Study:
Interventional
Study Design:
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Outcome Measure:
Number of patients with at least one lesion not detected on the MRI lesions
Outcome Time Frame:
3 months and 7 months
Safety Issue:
No
Authority:
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study ID:
STIC/10/03
NCT ID:
NCT01309334
Start Date:
February 2011
Completion Date:
November 2013
Related Keywords:
- Multiple Myeloma
- MRI
- PET-scan
- multiple myeloma
- prognosis
- pharmacoeconomic analysis
- Multiple Myeloma
- Neoplasms, Plasma Cell
Name | Location |
|---|
